8h agoSeeking AlphaBULLISH 78Product/PR
Tandem jumps on FDA clearance of Tandem Mobi tubeless insulin pump
Tandem Diabetes Care shares rise about 13% after FDA clears tubeless Mobi, with up to seven-day wear and estimated 50% pharmacy coverage.
Archived explainer. For the current picture see today's TNDM page.
Why Is TANDEM DIABETES CARE (TNDM) Stock Up Today?
By the Top Tier Newswire AI Desk · November 13, 2026 at 3:07 PM ET · reviewed against 10 wire stories
TANDEM DIABETES CARE (TNDM) is up +15.71% in the latest session. Our newswire has captured 10 stories on TNDM across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Tandem Diabetes Care (TNDM) shares rose 15.71% to $20.26 on Thursday, driven by the U.S. Food and Drug Administration’s clearance of its tubeless Mobi insulin delivery system. The approval marks a significant product milestone for the company, which is now positioning the device as the first tubeless automated insulin delivery system with up to seven days of wear.
What Happened
The FDA cleared the Tandem Mobi tubeless cartridge and infusion set, expanding the options available to people living with diabetes. The company stated that this clearance creates more possibilities for patients to experience the benefits of its Control-IQ+ AI technology. Tandem Diabetes Care filed a Form 8-K on November 13, 2026, disclosing the event under Item 8.01. The company plans a full U.S. commercial launch of the tubeless Mobi in the first half of 2027. Existing Mobi pumps are compatible with the new system. The device offers both tubed and tubeless wear options, providing flexibility for users.
What The Data Shows
The stock opened at $17.59 and reached a session high of $20.26 at 3:05 PM ET. Volume stood at 2.4 million shares, which is 1.1 times the three-month daily average. The company has a market capitalization of $1.3 billion and remains unprofitable, with a trailing twelve-month EPS of negative $0.72. Revenue grew 6.8% over the same period, while the net margin was negative 4.6%. The stock has a beta of 1.60 and trades within a 52-week range of $12.26 to $29.65. Over the last eight sessions, the stock moved down 0.8% from $17.65 to $17.51. On November 13, the stock printed 16 fresh 52-week highs and one fresh 52-week low. Recent insider activity includes one sale totaling $33,000 by director Christopher J. Twomey on October 27, 2026. Congressional disclosures show three buys and one sell in the last 90 days, including a purchase by Representative Gilbert Ray Cisneros, Jr. in September 2026.
What To Watch
Investors will monitor the company’s progress toward the planned first-half 2027 commercial launch of the tubeless Mobi system.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TNDM by the numbers
Last: $20.26Session: +15.71%7 sessions: +5.35%Coverage: 10 stories / 7 sourcesAI sentiment: 70/100 (bullish)Mkt cap: $1.3B52w: $12.26 to $29.65
The headlines behind the move
8h agoMarketWatchBULLISH 74Product/PR
Tandem Diabetes Care Shares Gain on FDA Clearance for Tubeless Insulin Delivery System
"This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology," Chief Executive Officer John Sheridan said.
10h agoSeeking AlphaBULLISH 74Product/PR
Tandem Diabetes Care jumps 12% on FDA clearance for tubeless Mobi
Tandem Diabetes Care shares rise 12% after FDA clears its tubeless Mobi system for up to seven days of wear; U.S.
10h agoInvesting.com MarketsBULLISH 74Product/PR
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump
10h agoGuruFocusBULLISH 78Product/PR
Tandem Diabetes (TNDM) Gains FDA Approval for First Tubeless Automated Insulin Delivery System
11h agoThe FlyBULLISH 74Product/PR
Tandem Diabetes receives FDA clearance for Tandem Mobi
11h agoSEC 8-KNEUTRAL 50General
TANDEM DIABETES CARE INC (TNDM) files 8-K: Item 8.01
Filed: 2026-11-13 AccNo: 0001438133-26-000148 Size: 140 KB Item 8.01: Other Events
11h agoStockTitanBULLISH 74Product/PR
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TNDM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier TNDM move explainers: 2026-11-13